XBiotech Inc. (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company that discovers and develops True Human antibody therapeutics. The company has no products approved for commercial sale and generates no product revenue, funding operations through capital raises and, previously, asset monetization. In 2019, XBiotech sold certain assets to Janssen Biotech, Inc. in a transaction that represented the company's only material source of net income to date. As of the 10-K filing for the fiscal year ended December 31, 2025, XBiotech's primary active program is Natrunix, a True Human antibody targeting IL-1 alpha, which completed a randomized, double-blinded, placebo-controlled clinical study in pancreatic cancer patients. Research and development expenses totaled $47.4 million for FY2025, a 26% increase from $37.8 million in FY2024. John Simard retired as President and CEO effective December 8, 2025, receiving a severance payment of $17.3 million and a 2025 annual bonus of $4.5 million. As of March 13, 2026, XBiotech had 30,487,731 common shares outstanding.

Revenue model

XBiotech has no commercial product revenue as of FY2025. The company's only historical income event was the 2019 asset sale to Janssen Biotech, Inc. Operations are funded through equity capital raises, with future revenue dependent on regulatory approval and commercialization of pipeline candidates.

Products and services

Natrunix (True Human antibody targeting IL-1 alpha): completed a 60-subject randomized placebo-controlled clinical study in advanced pancreatic cancer in combination with chemotherapy, with the last open-label extension dose administered in April 2025. The company's antibody platform is branded as True Human antibody technology.

Customers and end markets

XBiotech has no commercial customers as of FY2025. Target end markets are oncology patients undergoing chemotherapy, with the pancreatic cancer study serving as the primary clinical focus. The company believes the IL-1 alpha mechanism may apply to other solid tumors treated with chemotherapy.

Value-chain role

XBiotech operates as a drug discovery and clinical development company. It has previously monetized assets through a sale to Janssen Biotech, Inc. (2019). It does not manufacture or commercialize approved products as of FY2025.

Geographic exposure

XBiotech is incorporated under the laws of British Columbia, Canada, and its common stock is listed on the NASDAQ Global Select Market. Specific geographic breakdown of operations or expenditures is not disclosed in the provided filing excerpts.

Source: SEC 10-K, filed 2026-03-13

Industry: Pharmaceutical Preparations Peers: Candel Therapeutics Inc Greenwich Lifesciences Inc Biostax Corp. INmune Bio Inc Syros Pharmaceuticals, Inc. Nuvectis Pharma Inc Olema Pharmaceuticals Inc Praxis Precision Medicines Inc Shattuck Labs Inc